Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Sanofi Ord Shs SNYNF

Healthcare

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Add To Watchlist

Recent & Breaking News (OTCPK:SNYNF)

Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor

PR Newswire January 12, 2021

Sanofi Wins Prestigious Drug Discovery Award for Innovative Rare Blood Clotting Disorder Treatment[1]

PR Newswire December 17, 2019

Sanofi Announces Licensing of Dupixent® ? (dupilumab) in the EU for the Treatment of Severe Asthma With Type 2 Inflammation[1]

PR Newswire May 8, 2019

Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union

PR Newswire September 28, 2017

What's Next For L'Oreal After The Death Of Billionaire Liliane Bettencourt?

Benzinga.com September 22, 2017

Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS

PR Newswire September 20, 2017

Alnylam Pharmaceutical Surges After Rare Disease Drug Meets Key Endpoints

Benzinga.com September 20, 2017

Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy

Business Wire September 20, 2017

Huge Supply Shortage Looms for Canada's Newest Industry

PR Newswire September 19, 2017

Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis

PR Newswire September 16, 2017

Patient-Driven Dose Titration with Sanofi's Toujeo Improved Blood Glucose Control Without Increasing Hypoglycemia Risk in Real-Life Clinical Practice

PR Newswire September 14, 2017

Daily Blood Glucose Measures in Phase 3 Clinical Trials Demonstrated Better Stability with Sanofi's Toujeo® vs. Insulin Glargine 100 Units/mL

PR Newswire September 13, 2017

Sanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL

PR Newswire September 12, 2017

Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma

PR Newswire September 11, 2017

Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma

PR Newswire September 8, 2017

Sanofi Receives Tentative FDA Approval of Admelog® (insulin lispro injection) 100 Units/mL

PR Newswire September 1, 2017

Assessing The Eligible Suitors For Estee Lauder If Acquisition Rumors Are True

Benzinga.com August 28, 2017

Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017

PR Newswire August 25, 2017

Mylan's Stock Is No Longer A Buy According To Analysts At Argus

Benzinga.com August 22, 2017

Technical Snapshots for These Drug Makers Stocks -- Pfizer, Eli Lilly, Merck, and Sanofi

PR Newswire August 17, 2017